Johnson & Johnson expanded its in vivo CAR-T strategy by paying $785 million upfront to work with Flagship Pioneering’s Sail Biomedicines and to obtain an option to acquire the company. The move signals growing competition for “in vivo” cell therapy approaches that aim to manufacture and deliver CAR-T components inside patients. The option structure gives J&J a staged path to deeper involvement while advancing development activities under the agreement. For the market, the deal reinforces how large-cap pharma is adding “platform bets” as it seeks to broaden cell-therapy pipelines beyond traditional ex vivo manufacturing. This transaction also highlights how Flagship’s ecosystem continues to convert platform-led cell therapy work into high-stakes partnering—potentially accelerating timelines for in vivo programs and related manufacturing know-how.